STOCK TITAN
  1. Home
  2. News
  3. RVNC

Revance Therapeutics, Inc. - RVNC STOCK NEWS

Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.

Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.

The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.

Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.

Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.

News

Revance to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces participation in upcoming investor conferences with key executives presenting fireside chats. CEO Mark Foley and CFO Tobin Schilke to present at Cowen 44th Annual Healthcare Conference on March 5, 2024, and CEO Mark Foley at Barclays Global Healthcare Conference on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
News

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) has received a permanent J-code for DAXXIFY, a treatment for cervical dystonia, streamlining reimbursement. The pivotal Phase 3 study results published in Neurology reinforce the product's long duration of effect and favorable safety profile. The study showed that DAXXIFY was effective, generally safe, and well-tolerated, with a median duration of effect of over 20 weeks. The U.S. therapeutic neuromodulator market opportunity for DAXXIFY is $2.7 billion, including the over $350 million cervical dystonia market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
-
News

Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference on February 7-8, 2024, in New York. CEO Mark J. Foley will be participating in a fireside chat on February 8 at 9:30a.m. EST. The live audio webcast will be available on the company's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
conferences
News

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reports a 22% increase in Q4 DAXXIFY® volume sold over Q3, with a projected 2024 product revenue guidance of at least $280 million. Preliminary unaudited Q4 and full year 2023 product revenue for DAXXIFY and RHA® Collection is estimated to be between $58 million and $59 million and $212 million and $213 million, respectively, representing approximately 28% and 80% YoY growth. The company expects to achieve positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
earnings
-
News

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

Rhea-AI Summary
RVNC: Revance Therapeutics Reports Q3 Total Revenue of $56.8M, DAXXIFY Approval for Cervical Dystonia, and Positive Sales Growth. Q3 DAXXIFY revenue of $22.0M, RHA Collection revenue of $32.1M, and total product revenue of $54.1M, a YoY increase of 107.5%. DAXXIFY approval by FDA for cervical dystonia marks a significant milestone in the therapeutics market. Conference call and webcast today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
earnings
-
News

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

Rhea-AI Summary
RVNC: Revance Therapeutics Appoints Erica Jordan as Chief Commercial Officer, Aesthetics. The company aims to drive DAXXIFY adoption and grow its RHA filler business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
management
News

Revance to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in two investor conferences: Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, at 11:30 A.M. EST, while the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023, at 3:00 P.M. EST. Interested parties can access the live audio webcasts from the company's website. Webcast replays will be available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
-
News

Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will release its third quarter 2023 financial results on November 8, 2023, after the market closes. A conference call and live webcast will be held on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested individuals can dial (833) 470-1428 to listen to the conference call or access the webcast link on the company's website. A webcast replay will be available until February 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
earnings
-
News

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Rhea-AI Summary
DAXXIFY® for Injection named to TIME’s list of the best inventions of 2023. DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation in neuromodulator formulation in more than 30 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
News

Revance Provides Corporate Update at Investor Day

Rhea-AI Summary
Revance Therapeutics hosts Investor Day, announces new pricing program for DAXXIFY®, expects long-term supply chain strategy to support over 80% adjusted gross margin. Expects to free up $20 million/year by exiting OPUL® payments business. Updates 2023 financial guidance, funded to breakeven and expects to be Adjusted EBITDA positive in 2025. Q3 2023 product revenue potential similar to Q2 2023 levels. Revised operating expense guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.31%
Tags
none

FAQ

What is the current stock price of Revance Therapeutics (RVNC)?

The current stock price of Revance Therapeutics (RVNC) is $3.67 as of January 23, 2025.

What is the market cap of Revance Therapeutics (RVNC)?

The market cap of Revance Therapeutics (RVNC) is approximately 380.5M.

What does Revance Therapeutics, Inc. specialize in?

Revance Therapeutics, Inc. specializes in developing, manufacturing, and commercializing novel botulinum toxin products for aesthetic and therapeutic uses.

What is the TransMTS® peptide delivery system?

The TransMTS® peptide delivery system is Revance's patented technology for delivering botulinum toxin A in both needle-free topical and injectable forms.

What are the main products of Revance Therapeutics?

The main products are DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA for Injection Aesthetics, the RHA Collection of dermal fillers, and the HintMD platform.

What is RT001?

RT001 is a topical gel in development by Revance, which could become the first commercially available non-injectable botulinum toxin dose form.

What are the business segments of Revance Therapeutics?

Revance operates through Product and Service segments, with the Products segment generating the majority of the revenue.

How does Revance's TransMTS technology benefit its products?

TransMTS technology allows for targeted and potentially longer-lasting delivery of botulinum toxin, addressing unmet needs in the neurotoxin market.

What is the significance of DaxibotulinumtoxinA?

DaxibotulinumtoxinA is a key product for both aesthetic and therapeutic uses, reflecting Revance's innovation in neuromodulation.

What is the RHA Collection?

The RHA Collection is a line of dermal fillers included in Revance's prestige aesthetics portfolio.

What is the HintMD platform?

HintMD is a platform included in Revance's aesthetics portfolio, enhancing their offerings in the aesthetic market.

How does Revance's Product segment contribute to its revenue?

The Product segment focuses on research and development of aesthetic and therapeutic products, generating the majority of Revance's revenue.
Stock RVNC logo
Revance Therapeutics, Inc.

Nasdaq:RVNC

RVNC Rankings

#3361 Ranked by Market Cap
N/A Ranked by Dividends

RVNC Stock Data

380.50M
95.97M
8.56%
82.84%
9.36%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NASHVILLE